CMS Open Payments · Program Year 2024
Biotissue Holdings Inc.
Biotissue Holdings Inc. reported $3,327,398.09 across General Payments, Research, and Ownership to 20,909 physicians and teaching hospitals across 21,216 transactions.
- $3.3M
- All-tracks total
- 21,216
- Transactions
- 20,909
- Recipients
- +$543.5K
- General Payments vs PY2023
Biotissue Holdings Inc. reported $3,327,398.09 across all CMS Open Payments tracks (General + Research + Ownership) to 20,909 physicians and teaching hospitals in Program Year 2024 - ranking #339 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,088,801.36, averaging $159.14 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biotissue-holdings-inc Biotissue Holdings Inc.
$3.3M · #339/1,925 · 0.0% industry · PY2024
- TOT $3.3M
- RANK #339
- SHARE 0.0%
- TXN 21,216
- RCP 20,909
- CAT 4
- GEN $2.1M
- ΔGEN +$543.5K
- TOP1 4.9%
- PY 2024
Volume peers
Nearest volume peer: Merit Medical Systems Inc ($3.3M)
Biotissue Holdings Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Biotissue Holdings Inc.'s CMS-reported General Payments increased by $543.5K (+35.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BIOTISSUE HOLDINGS INC.PY2023: BIOTISSUE HOLDINGS INC.PY2024: BIOTISSUE HOLDINGS INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,545,274.33
- PY2024
- $2,088,801.36
What the Data Shows for Biotissue Holdings Inc.
Averaging $156.83 per transaction and $159.14 per recipient, Biotissue Holdings Inc.'s Program Year 2024 total comes to $3,327,398.09 across 21,216 transactions and 20,909 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #339 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
19,743 transactions worth $902.3K make "Food and Beverage" the top general-payment category in the 4-category breakdown below, 43.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Biotissue Holdings Inc.'s 4-category general-payment breakdown at $902.3K, 43.2% of the reported total.
Biotissue Holdings Inc. reports 4 general-payment categories - the top three are Food and Beverage (43.2%), Consulting Fee (33.0%), and Travel and Lodging (12.9%). The remaining 1 category make up 10.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Biotissue Holdings Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $902.3K | 19,743 | 43.2% |
| Consulting Fee | $689.1K | 220 | 33.0% |
| Travel and Lodging | $270.3K | 857 | 12.9% |
| Compensation for Faculty or Speaker (Medical Education) | $227.1K | 89 | 10.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $326,440.85 (15.6%) of $2,088,801.36 in this company's General Payments records across 7,392 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Biotissue Holdings Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Neel Rajendra Desai
$101,652.27 across 26 reported transactions
- 2
Michael James Bauer
$72,055.00 across 11 reported transactions
- 3
Brian J Bear
$53,141.73 across 11 reported transactions
- 4
Jason Douglas Bullajian
$50,204.86 across 47 reported transactions
- 5
Brett Bielory
$49,386.99 across 64 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Biotissue Holdings Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Biotissue Holdings Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Biotissue Holdings Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Paratek Pharmaceuticals, Inc.
Oyster Point Pharma, Inc.
Nielsen BioSciences, Inc.
Elekta, Inc.
LEO Pharma Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.